New study tests resilience training for lymphoma survivors
NCT ID NCT07014293
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a mind-body resilience group program can help lymphoma survivors cope better after finishing treatment. Researchers will enroll 254 adults who are within two years of completing curative therapy. Participants will either receive enhanced usual care or join a program that teaches relaxation, stress recognition, and positive thinking skills. The goal is to see if the program reduces anxiety and improves coping.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mind-body resilience group program (SMART3RP-Lymphoma) including relaxation response, cognitive behavioral therapy, and positive psychology
What this could lead to
If it works, this could provide a practical, non-drug way to help lymphoma survivors manage stress and improve their quality of life after treatment.
What could go wrong
This is a relatively small, early-stage trial testing a behavioral program, so results may not apply to all survivors. The program requires active participation and may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mass General Brigham
Boston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact